ArticleDiscover oncology2025
Development and validation of a machine learning-based pathomics nomogram for prognostic prediction in endometrial cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndometrial cancer (EC) is a common gynecologic malignancy with increasing incidence and notable molecular heterogeneity. This study aimed to develop a non-invasive, cost-effective prognostic model using pathomics features extracted from histopathological images.
methodsWe retrospectively analyzed hematoxylin and eosin (H&E)-stained whole slide images (WSIs) and clinical data from 514 EC patients in the TCGA-UCEC cohort. Tumor regions were manually annotated, preprocessed, and tiled into patches. Using CellProfiler, 728 high-dimensional quantitative features were extracted per case. Feature selection was performed through univariate Cox regression followed by LASSO regression to build a prognostic risk score. A nomogram integrating pathomics and clinical variables was constructed and evaluated.
resultsThe final prognostic model identified a panel of pathomics features significantly associated with overall survival. Patients in the high-risk group exhibited significantly worse survival outcomes compared to those in the low-risk group (p < 0.001). In both training and validation cohorts, the model demonstrated robust predictive accuracy, with AUCs of 0.806 and 0.782 for 3-year survival, respectively. The nomogram integrating clinical parameters and the pathomics score achieved an AUC of 0.791 and showed good calibration. Multivariate analysis confirmed the independent prognostic value of the pathomics signature. Subgroup analyses revealed consistent performance across molecular subtypes and FIGO stages.
conclusionThis study presents a validated pathomics-based model that accurately predicts prognosis in EC patients using routine H&E slides. It provides a scalable, low-cost tool for risk stratification and personalized management in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.